Management of Coagulopathy in ICU Patients
Manage ICU coagulopathy by first distinguishing between bleeding versus thrombotic phenotypes, then apply targeted interventions: for massive bleeding use high-ratio transfusion (≥1:2 plasma:RBC), point-of-care testing to guide therapy, and tranexamic acid within 90 minutes of injury for trauma; for sepsis-induced coagulopathy, diagnose using ISTH criteria and treat the underlying infection while providing supportive care. 1, 2, 3
Algorithmic Approach to ICU Coagulopathy
Step 1: Identify the Clinical Phenotype
ICU coagulopathy presents in two dominant patterns that require fundamentally different management 4:
- Hemorrhagic coagulopathy: Hypocoagulable state with hyperfibrinolysis (trauma, massive bleeding, dilutional)
- Thrombotic coagulopathy: Prothrombotic with antifibrinolytic phenotype (sepsis-induced coagulopathy/DIC)
Step 2: Classify Bleeding Severity (If Hemorrhagic)
Massive bleeding is defined as >10 units RBC in 24 hours OR >4 units in 1 hour 1. This distinction is critical as management strategies differ significantly.
Step 3: Apply Specific Management Based on Phenotype
For Massive Bleeding (Hemorrhagic Phenotype)
Transfusion Strategy
Use high-ratio transfusion protocols with at least 1 unit plasma per 2 units packed RBCs (1:2 FFP:RBC ratio) in trauma patients 1. While observational data suggested mortality benefits with ratios up to 1:1:1 (plasma:platelets:RBC), randomized trials showed no additional mortality benefit beyond 1:2 ratios, though the evidence remains conditional due to low certainty 1.
Critical caveat: For non-traumatic massive bleeding, evidence is insufficient to make firm ratio recommendations, so individualize based on point-of-care testing 1.
Tranexamic Acid (TXA)
Administer TXA within 90 minutes of injury for trauma patients 3. This represents a significant update from the traditional 3-hour window. Recent analysis demonstrates:
- Within 90 minutes: 36% relative risk reduction in 28-day mortality (adjusted RR 0.64,95% CI 0.50-0.82)
- Beyond 90 minutes: No mortality benefit (adjusted RR 1.04,95% CI 0.74-1.47)
Dosing: 1g IV bolus immediately, followed by 1g infusion over 8 hours 3.
Point-of-Care Testing
Utilize viscoelastic testing (TEG/ROTEM) to guide component therapy rather than relying solely on conventional coagulation tests 1. This allows real-time assessment of clot formation, strength, and fibrinolysis to target specific deficiencies.
For Sepsis-Induced Coagulopathy (Thrombotic Phenotype)
Diagnosis
Apply the ISTH Sepsis-Induced Coagulopathy (SIC) score 2:
- Platelet count: <100 × 10⁹/L (1 point), <150 × 10⁹/L (2 points)
- PT ratio: >1.2 (1 point), >1.4 (2 points)
- SOFA score: 1 point for score of 1,2 points for score ≥2
- Total ≥4 points = SIC diagnosis
For overt DIC, use ISTH overt DIC criteria requiring ≥5 points including fibrinogen <100 mg/dL and FDP/D-dimer elevation 2.
Management Principles
Treat the underlying sepsis aggressively as the primary intervention 2. Sepsis-associated DIC differs fundamentally from malignancy-associated DIC by exhibiting excessive suppression of fibrinolysis (via PAI-1 overproduction), leading to prothrombotic complications and organ dysfunction rather than bleeding 2.
Anticoagulation considerations: While specific anticoagulant therapy for sepsis-induced coagulopathy remains controversial, the pathophysiology suggests potential benefit in selected patients with overt DIC, though this requires careful risk-benefit assessment 2.
For Non-Massive Bleeding
Adopt restrictive transfusion thresholds and use targeted factor replacement based on specific deficiencies identified by laboratory testing 1. The ESICM guideline generated 26 recommendations but acknowledged that 10 clinical questions had insufficient evidence, highlighting the need for individualized approaches in non-massive bleeding scenarios 1.
Critical Pitfalls to Avoid
Survivorship bias in transfusion ratios: Early observational studies showing dramatic benefits of high-ratio transfusion were confounded by patients dying before plasma could be thawed. RCT evidence is more modest 1.
Delayed TXA administration: The therapeutic window is narrower than previously thought—aim for <90 minutes, not <3 hours 3.
Ignoring the coagulopathy phenotype: Treating septic DIC like hemorrhagic coagulopathy (or vice versa) can worsen outcomes. Septic coagulopathy is prothrombotic despite abnormal labs 2, 4.
Over-reliance on conventional coagulation tests: PT/INR and aPTT poorly predict bleeding risk in critically ill patients. Point-of-care viscoelastic testing provides more actionable information 1.
Assuming all coagulopathy requires correction: Not all laboratory abnormalities require treatment—focus on clinically significant bleeding or high thrombotic risk 4.
Special Populations
Patients on novel anticoagulants: Consider specific reversal agents when available (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) in life-threatening bleeding 5.
Extracorporeal support (ECMO): These patients develop unique consumptive coagulopathy requiring specialized monitoring and management protocols 6.